Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation
Standard
Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation. / Schneidawind, Corina; Duerr-Stoerzer, Silke; Faul, Christoph; Kanz, Lothar; Weisel, Katja; Bethge, Wolfgang; Schneidawind, Dominik.
in: CLIN TRANSPLANT, Jahrgang 31, Nr. 7, 07.2017.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation
AU - Schneidawind, Corina
AU - Duerr-Stoerzer, Silke
AU - Faul, Christoph
AU - Kanz, Lothar
AU - Weisel, Katja
AU - Bethge, Wolfgang
AU - Schneidawind, Dominik
N1 - © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
PY - 2017/7
Y1 - 2017/7
N2 - BACKGROUND: The role of allogeneic hematopoietic cell transplantation (HCT) for the treatment of multiple myeloma is controversial. However, the introduction of proteasome inhibitors and immunomodulatory drugs might influence outcomes in case of relapse or refractory disease after allogeneic HCT.METHODS: We report 41 consecutive patients that underwent allogeneic HCT for the treatment of relapsed or refractory multiple myeloma.RESULTS: Three-year event-free survival (EFS) and overall survival (OS) of the whole cohort were 15% and 51%, respectively. In a subgroup analysis, allogeneic HCT after a second high-dose chemotherapy with autologous stem cell support was associated with a decreased 3-year EFS (6% vs 24%, P=.04) and OS (35% vs 64%, P=.09). In case of relapse or refractory disease after allogeneic HCT, the treatment with proteasome inhibitors or immunomodulatory drugs significantly improved survival (1-year OS 79% vs 29%, P=.001).CONCLUSION: The incorporation of proteasome inhibitors and immunomodulatory drugs into transplant protocols has the potential to improve outcomes and refine the role of allogeneic HCT for the treatment of multiple myeloma as a platform for long-term disease control.
AB - BACKGROUND: The role of allogeneic hematopoietic cell transplantation (HCT) for the treatment of multiple myeloma is controversial. However, the introduction of proteasome inhibitors and immunomodulatory drugs might influence outcomes in case of relapse or refractory disease after allogeneic HCT.METHODS: We report 41 consecutive patients that underwent allogeneic HCT for the treatment of relapsed or refractory multiple myeloma.RESULTS: Three-year event-free survival (EFS) and overall survival (OS) of the whole cohort were 15% and 51%, respectively. In a subgroup analysis, allogeneic HCT after a second high-dose chemotherapy with autologous stem cell support was associated with a decreased 3-year EFS (6% vs 24%, P=.04) and OS (35% vs 64%, P=.09). In case of relapse or refractory disease after allogeneic HCT, the treatment with proteasome inhibitors or immunomodulatory drugs significantly improved survival (1-year OS 79% vs 29%, P=.001).CONCLUSION: The incorporation of proteasome inhibitors and immunomodulatory drugs into transplant protocols has the potential to improve outcomes and refine the role of allogeneic HCT for the treatment of multiple myeloma as a platform for long-term disease control.
KW - Adult
KW - Aged
KW - Female
KW - Follow-Up Studies
KW - Graft Rejection
KW - Graft Survival
KW - Graft vs Host Disease
KW - Hematopoietic Stem Cell Transplantation
KW - Humans
KW - Immunomodulation
KW - Male
KW - Middle Aged
KW - Multiple Myeloma
KW - Neoplasm Recurrence, Local
KW - Prognosis
KW - Proteasome Inhibitors
KW - Retrospective Studies
KW - Risk Factors
KW - Transplantation Conditioning
KW - Transplantation, Homologous
KW - Journal Article
U2 - 10.1111/ctr.12994
DO - 10.1111/ctr.12994
M3 - SCORING: Journal article
C2 - 28470884
VL - 31
JO - CLIN TRANSPLANT
JF - CLIN TRANSPLANT
SN - 0902-0063
IS - 7
ER -
